Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial

Claudio Gobbi, Dominik S Meier, François Cotton, Martina Sintzel, David Leppert, Charles R G Guttmann, Chiara Zecca, Claudio Gobbi, Dominik S Meier, François Cotton, Martina Sintzel, David Leppert, Charles R G Guttmann, Chiara Zecca

Abstract

Background: Natalizumab (NTZ) discontinuation leads to multiple sclerosis reactivation.The objective of this study is to compare disease activity in MS patients who continued on NTZ treatment to those who were switched to subcutaneous interferon 1b (IFNB) treatment.

Methods: 1-year randomized, rater-blinded, parallel-group, pilot study (ClinicalTrial.gov ID: NCT01144052). Relapsing remitting MS patients on NTZ for ≥12 months who had been free of disease activity on this therapy (no relapses and disability progression for ≥6 months, no gadolinium-enhancing lesions on baseline MRI) were randomized to NTZ or IFNB. Primary endpoint was time to first on-study relapse. Additional clinical, MRI and safety parameters were assessed. Analysis was based on intention to treat.

Results: 19 patients (NTZ n=10; IFNB n=9) with similar baseline characteristics were included. 78% of IFNB treated patients remained relapse free (NTZ group: 100%), and 25% remained free of new T2 lesions (NTZ group: 62.5%). While time to first on-study relapse was not significantly different between groups (p=0.125), many secondary clinical and radiological endpoints (number of relapses, proportion of relapse free patients, number of new T2 lesions) showed a trend, or were significant (new T2 lesions at month 6) in favoring NTZ.

Conclusions: De-escalation therapy from NTZ to IFNB over 1 year was associated with some clinical and radiological disease recurrence. Overall no major safety concerns were observed.

Figures

Figure 1
Figure 1
Mean number of new T2 lesions (nT2L) and gadolinium enhancing lesions (Gd+L) per patient at baseline and at month 3, 6, 9 and 12 of study (statistical analysis was performed with non parametric tests and reported in Results and Table 2).
Figure 2
Figure 2
Kaplan Meier survival curves representing the probability of being free of nT2L lesions throughout the study period under de-escalation therapy with INFB or continued NTZ.

References

    1. Kappos L, Bates D, Edan G. et al.Natalizumab treatment for multiple sclerosis: updated recommendations for patients selection and monitoring. Lancet Neurol. 2011;10:745–758. doi: 10.1016/S1474-4422(11)70149-1.
    1. Cada DJ, Levien T, Baker DE. Natalizumab. Hosp Pharm. 2005;40:336–346.
    1. O'Connor PW, Goodman A, Kappos L. et al.Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurol. 2011;76:1858–1865. doi: 10.1212/WNL.0b013e31821e7c8a.
    1. Killestein J, Vennegoor A, Strijbis EM. et al.Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68(3):392–395. doi: 10.1002/ana.22074.
    1. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol. 2010;68(3):395–399. doi: 10.1002/ana.22163.
    1. Polman CH, Reingold SC, Edan G. et al.Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703.
    1. Moraal B, van den Elskamp IJ, Knol DL. et al.Long-interval T2-weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials. Ann Neurol. 2010;67:667–675.
    1. Khatri BO, Man S, Giovannoni G. et al.Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurol. 2009;72(5):402–409. doi: 10.1212/01.wnl.0000341766.59028.9d.
    1. Havla J, Gerdes LA, Meinl I. et -escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol. 2011;258(9):1665–1669. doi: 10.1007/s00415-011-5996-y.
    1. Vellinga MM, Castelijns JA, Barkhof F. et al.Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurol. 2008;70:1150–1151.
    1. Fox RJ, Kappos L. Is natalizumab overshooting its rebound? Neurol. 2008;70:1173–1174.
    1. Fox R, Kappos L, Cree B. et al.Effects of a 24-week natalizumab treatment interruption on clinical and radiological parameters of multiple sclerosis disease activity: the RESTORE study. Mult Scler J. 2011;17(S10):S509–S510.
    1. Rossi S, Motta C, Studer V. et al.Effect of Glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol. 2012;20(1):87–94.
    1. Magraner MJ, Coret F, Navarré A. et al.Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-months observational study. J Neurol. 2011;258(10):1805–1811. doi: 10.1007/s00415-011-6019-8.
    1. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Annal Neurol. 2001;49:270–277.
    1. Polman CH, O'Connor PW, Havrdova E. et al.A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910. doi: 10.1056/NEJMoa044397.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner